Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9308268rdf:typepubmed:Citationlld:pubmed
pubmed-article:9308268lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:9308268lifeskim:mentionsumls-concept:C0030193lld:lifeskim
pubmed-article:9308268lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:9308268lifeskim:mentionsumls-concept:C0002895lld:lifeskim
pubmed-article:9308268lifeskim:mentionsumls-concept:C0220931lld:lifeskim
pubmed-article:9308268lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:9308268lifeskim:mentionsumls-concept:C1273870lld:lifeskim
pubmed-article:9308268lifeskim:mentionsumls-concept:C2825951lld:lifeskim
pubmed-article:9308268pubmed:issue4lld:pubmed
pubmed-article:9308268pubmed:dateCreated1997-10-30lld:pubmed
pubmed-article:9308268pubmed:abstractTextA cohort of patients with sickle cell disease, consisting of children, adolescents, and adults, who reported experiencing three or more episodes of vaso-occlusive pain the preceding year, were enrolled in a prospective two-period treatment protocol. Following a 4-month conventional treatment baseline phase, a supplemental cognitive-behavioral pain management program that centered on self-hypnosis was implemented over the next 18 months. Frequency of self-hypnosis group straining sessions began at once per week for the first 6 months, became biweekly for the next 6 months, and finally occurred once every third week for the remaining 6 months. Results indicate that the self-hypnosis intervention was associated with a significant reduction in pain days. Both the proportion of "bad sleep" nights and the use of pain medications also decreased significantly during the self-hypnosis treatment phase. However, participants continued to report disturbed sleep and to require medications on those days during which they did experience pain. Findings further suggest that the overall reduction in pain frequency was due to the elimination of less severe episodes of pain. Non-specific factors may have contributed to the efficacy of treatment. Nevertheless, the program clearly demonstrates that an adjunctive behavioral treatment for sickle cell pain, involving patient self-management and regular contact with a medical self-hypnosis team, can be beneficial in reducing recurrent, unpredictable episodes of pain in a patient population for whom few safe, cost-effective medical alternatives exist.lld:pubmed
pubmed-article:9308268pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9308268pubmed:languageenglld:pubmed
pubmed-article:9308268pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9308268pubmed:citationSubsetIMlld:pubmed
pubmed-article:9308268pubmed:statusMEDLINElld:pubmed
pubmed-article:9308268pubmed:monthOctlld:pubmed
pubmed-article:9308268pubmed:issn0020-7144lld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:OrneM TMTlld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:OrneE CEClld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:DingesD FDFlld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:ShapiroB SBSlld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:Ohene-Frempon...lld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:WhitehouseW...lld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:BloomP BPBlld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:DampierCClld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:BauerN KNKlld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:CarlinM MMMlld:pubmed
pubmed-article:9308268pubmed:authorpubmed-author:GillenK AKAlld:pubmed
pubmed-article:9308268pubmed:issnTypePrintlld:pubmed
pubmed-article:9308268pubmed:volume45lld:pubmed
pubmed-article:9308268pubmed:ownerNLMlld:pubmed
pubmed-article:9308268pubmed:authorsCompleteYlld:pubmed
pubmed-article:9308268pubmed:pagination417-32lld:pubmed
pubmed-article:9308268pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:meshHeadingpubmed-meshheading:9308268-...lld:pubmed
pubmed-article:9308268pubmed:year1997lld:pubmed
pubmed-article:9308268pubmed:articleTitleSelf-hypnosis training as an adjunctive treatment in the management of pain associated with sickle cell disease.lld:pubmed
pubmed-article:9308268pubmed:affiliationUnit for Experimental Psychiatry, University of Pennsylvania School of Medicine, Philadelphia 19104-6021, USA.lld:pubmed
pubmed-article:9308268pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9308268pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9308268pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9308268pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9308268pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9308268lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9308268lld:pubmed